As from 1st April, Sue will be furloughed. The rules state that Sue will not be able to carry out any work for the centre during this time. Therefore emails will be dealt with by Dave Webb or Keith Beswick.
Dave Webb
Trustee
As from 1st April, Sue will be furloughed. The rules state that Sue will not be able to carry out any work for the centre during this time. Therefore emails will be dealt with by Dave Webb or Keith Beswick.
Dave Webb
Trustee
The centre will be closed until further notice. Updates will be provided by this newsletter. Also you can follow us on facebook ‘omstc’ Sue will continue to answer emails. You can contact her on ms.therapy@btconnect.com
The Trustees have made a decision to keep the centre shut for at least another week (23-27 March). Please keep checking facebook or the blog for further updates. Sue is also checking emails ms.therapy@btconnect.com Keep safe everyone.
We are highly suspicious that someone who has attended the centre has clovid 19 virus. It has therefore been decided by the Chair that we have to shut for the rest of this week. Sue will be contacting everyone who has been in the centre in the last 2 weeks to see if they have any symptoms. If there are none, we will be open again on Tuesday 24th March. If anyone does have symptoms we will be shut for a further week, with a view to re-opening again on 30th March.
PLEASE LET THE CENTRE KNOW BY EMAIL (ms.therapy@btconnect.com) URGENTLY IF YOU HAVE ANY SYMPTOMS AND YOU HAVE BEEN TO THE CENTRE WITHIN THE LAST 2 WEEKS. REMEMBER – EMAIL NOT PHONE.
I am sorry for any inconvenience caused.
Oxfordshire MS Therapy Centre
Preventing the Spread of Coronavirus
Information Sheet
Coronavirus Public Information: Please follow all guidance being provided by HM Government and NHS regarding the containment of the virus.
The news is changing rapidly, please keep up to date with the national and local developments.
At the Centre we have provided additional hand sanitisers, tissues, waste bins, and displayed posters reminding people to regularly wash their hands along with the “Catch it, Kill it, Bin it” message.
If you are feeling unwell, or are in any doubt, please do not attend the Centre and follow the advice on the NHS 111 website or by calling the NHS 111 Helpline.
Source Multiple Sclerosis International Federation: The coronavirus and MS – what you need to know
The ‘novel coronavirus’ (recently named by the World Health Organization as COVID-19) is a respiratory illness that has not previously been seen in humans. COVID-19 is a strain of coronavirus that was first detected in China in December 2019, and has since spread to other parts of the world.
What does COVID-19 mean for people living with MS?
As this strain of the coronavirus is new, we still need to learn more about how it may affect people with MS.
Many disease-modifying therapies (DMTs) for MS work by suppressing or modifying the immune system. We know that people with MS who are receiving these therapies can face an increased risk of complications related to viral infections.
If you are taking a DMT and are either exposed to COVID-19 or are confirmed to have the COVID-19 infection, please contact your neurologist or other medical professionals. Read on.
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
The results were published in an article, “Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice,” in the journal Neurology Clinical Practice.
Tysabri, marketed by Biogen, is an antibody treatment that blocks immune system cells from moving into the brain and spinal cord. It was approved by the U.S. Food and Drug Administration (FDA) as a treatment for MS in 2004, but was pulled from the market after being linked to a rare neurological disorder called progressive multifocal leukoencephalopathy (PML). Read on.
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.
Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. In doing so, the therapy is expected to limit the inflammatory processes that cause damage to the nervous system in MS.
It may also have applications in other conditions, including other neurological diseases and certain cancers. Read on.
100 club winners for January
1st prize: Shirley Ray
2nd prize: Julia Gower
3rd prize: Sue Doran